Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chaudhry, V.
Right arrow Articles by Griffin, J.W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chaudhry, V.
Right arrow Articles by Griffin, J.W.
Related Collections
Right arrow Peripheral neuropathy
Right arrow Chemotherapy-tumor
Right arrow All Toxicology

Neurology 2003;60:337-340
© 2003 American Academy of Neurology
Brief Communications

Toxic neuropathy in patients with pre-existing neuropathy

V. Chaudhry, MD, M. Chaudhry, MD, T.O. Crawford, MD, E. Simmons-O’Brien, MD and J.W. Griffin, MD

From the Departments of Neurology (Drs. V. Chaudhry, Crawford, and Griffin) and Dermatology (Dr. Simmons-O’Brien), Johns Hopkins University School of Medicine; and Department of Oncology (Dr. M. Chaudhry), Greater Baltimore Medical Center, Baltimore, MD.

Address correspondence and reprint requests to Dr. Chaudhry, 601 North Caroline Street, Suite 5072A, Baltimore, MD 21287; e-mail: vchaudh{at}jhmi.edu

The authors report significant worsening of a pre-existing neuropathy in six patients who received "non-toxic" dosages of known neurotoxic agents. Before treatment, baseline total neuropathy score (TNS) averaged 9.5 (range 0 to 19). After chemotherapy (Taxol [125 to 175 mg/m2 x 4]; vincristine [2 to 5 mg]; cisplatin [40 mg/m2 x 8]; and thalidomide [60 g]), the TNS averaged 22 (range 13 to 29). The authors conclude that functionally disabling toxic neuropathy can occur in patients with pre-existing neuropathy at standard doses.




This article has been cited by other articles:


Home page
 ptjournalHome page
L. S Gilchrist, M. L. Galantino, M. Wampler, V. G Marchese, G S. Morris, and K. K Ness
A Framework for Assessment in Oncology Rehabilitation
Physical Therapy, March 1, 2009; 89(3): 286 - 306.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. A. Argyriou, G. Iconomou, and H. P. Kalofonos
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature
Blood, September 1, 2008; 112(5): 1593 - 1599.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
J.B. Epstein, S. Elad, E. Eliav, R. Jurevic, and R. Benoliel
Orofacial Pain in Cancer: Part II--Clinical Perspectives and Management
Journal of Dental Research, June 1, 2007; 86(6): 506 - 518.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. Cavaletti, G. Bogliun, L. Marzorati, A. Zincone, M. Piatti, N. Colombo, G. Parma, A. Lissoni, F. Fei, S. Cundari, et al.
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale
Neurology, November 11, 2003; 61(9): 1297 - 1300.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.